This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Acceleron And Celgene Report New Interim Clinical Data From Phase 2 Trial Of Sotatercept In Beta-Thalassemia At 2013 American Society Of Hematology Annual Meeting

Stocks in this article: XLRN

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner Celgene reported new interim data at the 55 th American Society of Hematology (ASH) Annual Meeting of sotatercept in patients with beta-thalassemia. Interim data presented from the ongoing phase 2 trial demonstrate dose dependent increases in hemoglobin in non-transfusion dependent beta-thalassemia patients. Beta-thalassemia is a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart.

The data were presented in a poster session by Maria Domenica Cappellini, M.D., University of Milan, Milan, Italy, an investigator of the phase 2 clinical trial. The presentation included new interim data from the 0.5 mg/kg dose level as well as longer term clinical data from patients in the 0.1 mg/kg and 0.3 mg/kg dose levels in the ongoing trial. The phase 2 clinical trial is an open label, dose escalation study designed to determine a safe and effective dose of sotatercept administered subcutaneously every three weeks in adult patients with beta-thalassemia. A total of twenty-five patients were enrolled in the first three dose cohorts; eight in the 0.1 mg/kg cohort, nine in the 0.3 mg/kg cohort, and eight in the 0.5 mg/kg cohort. Eighteen patients have non-transfusion dependent beta-thalassemia and seven patients have transfusion dependent beta-thalassemia. The phase 2 trial is ongoing and currently enrolling patients at a dose level of 0.75 mg/kg to determine a safe and effective dose range for the pivotal trial.

The poster containing these data is available on the Acceleron website under the Publications section.

Sotatercept Clinical Data Overview

  • Dose dependent increases in hemoglobin were observed across the three dose levels evaluated
  • Within the first two months of receiving the first dose of sotatercept:
    • 84% of non-transfusion dependent patients in each of the 0.5 and 0.3 mg/kg dose levels achieved at least a 1 g/dL increase in hemoglobin, while none of the non-transfusion dependent patients at the lowest dose level (0.1 mg/kg) achieved this threshold
    • 33%, 16% and 0% of non-transfusion dependent patients achieved a hemoglobin increase of at least 2 g/dL in the 0.5, 0.3, and 0.1 mg/kg dose levels, respectively
  • Five of six non-transfusion dependent patients treated at the 0.3 mg/kg dose level had a sustained increase in hemoglobin through at least 10 cycles of treatment (3 weeks per cycle)
  • A statistically significant relationship (p<0.001) between drug exposure and maximum increase in hemoglobin during the first three cycles was demonstrated across the three dose levels tested
  • Sotatercept was generally safe and well tolerated in patients at all dose levels evaluated

“Because patients with non-transfusion dependent beta-thalassemia often suffer from severe and life-threatening complications from their disease and there are no approved drugs to treat the anemia of beta-thalassemia, the unmet need is enormous” said Matthew Sherman, M.D., Chief Medical Officer of Acceleron. “Acceleron is encouraged by these interim data as they continue to demonstrate the potential for sotatercept to produce a clinically meaningful increase in hemoglobin for this underserved patient population.”

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,725.01 +263.69 1.60%
S&P 500 1,954.43 +27.32 1.42%
NASDAQ 4,456.9960 +74.1490 1.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs